Sheri L. Booten
Isis Pharmaceuticals
29 Papers
157 Citations
Sheri L. Booten is an academic researcher from Isis Pharmaceuticals. The author has contributed to research in topics: Hepcidin & Transferrin saturation. The author has an hindex of 16, co-authored 28 publications.
Chat about Author
Papers
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting.
Christine Esau,Scott Davis,Susan F. Murray,Xing Xian Yu,Sanjay K. Pandey,Michael Pear,Lynnetta Watts,Sheri L. Booten,Mark J. Graham,Robert Mckay,Amuthakannan Subramaniam,Stephanie Propp,Bridget Lollo,Susan M. Freier,C. Frank Bennett,Sanjay Bhanot,Brett P. Monia +16 more
TL;DR: IMR-122 inhibition in a diet-induced obesity mouse model resulted in decreased plasma cholesterol levels and a significant improvement in liver steatosis, accompanied by reductions in several lipogenic genes, suggesting that miR- 122 may be an attractive therapeutic target for metabolic disease.
2.2K
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash,Mark J. Graham,Jinghua Yu,Rick Carty,Audrey Low,Alfred E. Chappell,Karsten Schmidt,Chenguang Zhao,Mariam Aghajan,Heather F. Murray,Stan Riney,Sheri L. Booten,Susan F. Murray,Hans Gaus,Jeff Crosby,Walt F. Lima,Shuling Guo,Brett P. Monia,Eric E. Swayze,Punit P. Seth +19 more
TL;DR: Triantennary N-acetyl galactosamine (GalNAc, GN3), a high-affinity ligand for the hepatocyte-specific asialoglycoprotein receptor (ASGPR), enhances the potency of second-generation gapmer antisense oligonucleotides (ASOs) 6–10-fold in mouse liver.
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
Xing Xian Yu,Susan F. Murray,Sanjay K. Pandey,Sheri L. Booten,Dingjiu Bao,Xiu-Zhen Song,Susan Kelly,Songyuan Chen,Robert Mckay,Brett P. Monia,Sanjay Bhanot +10 more
TL;DR: Reduction of DGAT2 expression in obese animals can reduce hepatic lipogenesis and hepatic steatosis as well as attenuate hyperlipidemia, thereby leading to an improvement in metabolic syndrome.
299
Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice
Shuling Guo,Carla Casu,Sara Gardenghi,Sheri L. Booten,Mariam Aghajan,Raechel Peralta,Andrew T. Watt,Sue Freier,Brett P. Monia,Stefano Rivella +9 more
TL;DR: Second generation antisense oligonucleotides (ASOs) targeting mouse Tmprss6 could be beneficial in individuals with hemochromatosis, β-thalassemia, and related disorders.
Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides
Elizabeth J. Ackermann,Shuling Guo,Merrill D. Benson,Sheri L. Booten,Sue Freier,S. Hughes,Tae-Won Kim,T. Jesse Kwoh,John B. Matson,Daniel A. Norris,Rosie Z. Yu,Andrew T. Watt,Brett P. Monia +12 more
TL;DR: Nonclinical and clinical results support the ongoing Phase 3 development of IONIS-TTRRx in patients with ATTR amyloidosis, a 2nd-Generation 2′-O-(2-methoxyethyl) modified “2′-MOE” antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the T TR transcript through an RNaseH1 mechanism of action.
133